Literature DB >> 8100339

Hormone replacement after breast cancer.

T J Powles, T Hickish, S Casey, M O'Brien.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8100339     DOI： 10.1016/0140-6736(93)91931-b

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.

Authors:  Rodney Baber; Martha Hickey; Michelle Kwik
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Hormone replacement therapy for survivors of breast and endometrial cancer.

Authors:  Philip J DiSaia; Wendy R Brewster
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

Review 3.  Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer.

Authors:  Kathleen I Pritchard; Humaira Khan; Mark Levine
Journal:  CMAJ       Date:  2002-04-16       Impact factor: 8.262

Review 4.  Chemoprevention of breast cancer: implications for postmenopausal women.

Authors:  Carol J Fabian; Bruce F Kimler
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Estrogen replacement therapy in women at increased risk for breast cancer.

Authors:  R Vassilopoulou-Sellin
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

6.  Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.

Authors:  C Derzko; S Elliott; W Lam
Journal:  Curr Oncol       Date:  2007-12       Impact factor: 3.677

7.  Hormone replacement therapy as treatment of breast cancer--a phase II study of Org OD 14 (tibilone).

Authors:  M O'Brien; A Montes; T J Powles
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

8.  Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.

Authors:  A Decensi; C Robertson; N Rotmensz; G Severi; P Maisonneuve; V Sacchini; P Boyle; A Costa; U Veronesi
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.